Life Sciences Archive » November, 2024

Life Sciences - November, 2024

222 articles

• A Look Back At Years Of Zantac Litigation: Timeline
• PTAB Finds Hormone Treatment Patent Claims Invalid
• Deloitte Posed As Consultant To Steal Vax Software, Suit Says
• PBM Says Opioid Ruling Ignored High Court's Privilege Stance
• Nonprofit Warns 3rd Circ. Against 'Abuse' In Merck Vax Case
• Amid Claims Of Bias, DEA To Kick Off Historic Pot Hearing
• Dissecting The Obviousness-Type Double Patenting Debate
• Up Next At The High Court: Transgender Care, Holocaust Art
• Hospital Sued For Firing Tech Who Reported Lax Drugmaking
• Service Providers Must Mitigate 'Secondary Target' Risks
• Congressional Dems Urge Biden For More Cannabis Reform
• Trump Taps Bhattacharya For National Institutes Of Health
• NIH Beats 4th Circ. Bid To Unmask COVID Researcher
• Beasley Allen Escapes Sanctions For J&J Deposition No Show
• Gilead Gets $31.8M In Calif. Case Over Counterfeit HIV Drugs
• Health Policy Predictions For Trump's Second Administration
• FDA Seeks Fines Against 18 Retailers Over E-Cig Sales
• Court Asked To Halt DEA's Pot Rescheduling Hearing
• Paul Hastings Seeks GenapSys CEO Depo In Malpractice Suit
• Flying Makes Me A Better Lawyer
• Navajo Nation's Diné College Awarded 2nd Medical Patent
• Mexico Floats Retaliation Against New Trump Tariffs
• Ex-Regeneron Director Says FMLA Suit Should Stay In Court
• 9th Circ.'s High Bar May Limit Keyword Confusion TM Claims
• Trump Vows Tariffs For Canada, Mexico, China On Day One
• Calif. Jury Delivers $35M Verdict In Eyedrop Trademark Row
• Calif. Panel Scraps Ex-Medical Supply Exec's $533K Fee Win
• DEA And Anti-Pot Group Reject Accusations Of Collusion
• Medical Info. Co. Beats Junk Fax Suit Over Free E-Book Offer
• Trump Patent Policy May Be Headed In Unexpected Direction
• Jury Finds Natera Owes Guardant $292.5M In False Ad Suit
• Ex-Epstein Becker Healthcare Ace Joins Polsinelli Team
• MVP: Cooley's Lila Hope
• What Trump's Next Term May Mean For Biz Immigration
• Trump Makes Picks For FDA, CDC And Surgeon General
• Natera's Conduct 'Despicable,' Guardant Says As Trial Wraps
• Pam Bondi's 'Greatest Hits' As Florida Attorney General
• CooperSurgical Product Caused Embryo Loss, Couple Say
• Mich. Justices Want To Know If 3M Water Challenge Is Moot
• Bondi Vowed Trump Payback. Ex-Colleagues Aren't Worried.
• Racing Patents To The Fed. Circ.: Collateral Estoppel Lessons
• Vitamin Co. Must Freeze Owner Payouts Amid $1.4M Tax Fight
• Walmart Class Attys In $123M Opioid Deal Seek $24.6M Fee
• Avante Health Parent Cleared To Sell For $72.5M In Ch. 11
• Halozyme Pulls €2B Bid After Evotec Fails To Engage In Talks
• MVP: Skadden's Graham Robinson
• UK Litigation Roundup: Here's What You Missed In London
• Circus Arts Make Me A Better Lawyer
• SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
• Boehringer Trial Over Zantac's Cancer Link Ends In Mistrial
• SEC Seeks More Data On Nasdaq Plan To Speed Up Delistings
• Trump Selects Ex-Fla. AG Pam Bondi As New AG Pick
• IP Atty Fights To Revive Allergan FCA Suit At 9th Circ.
• In Tight Vote, Senate Panel OKs Bill To Set New PTAB Limits
• 3 Ways To Train Junior Lawyers In 30 Minutes Or Less
• MVP: Fenwick's Douglas Cogen
• Musk, Ramaswamy Say High Court Rulings OK Federal Cuts
• Ex-Pharma CEO Demands Legal Fees For SEC Probe
• USPTO Unveils Patent Fee Hikes Set To Take Effect In January
• DEA Accused Of Colluding With Reform Foes In Pot Row
• How AstraZeneca Ruling Could Change Dosage Patent Claims
• PBMs Sue To Block FTC's In-House Insulin Pricing Case
• 3 States To Challenge Abortion Regs After Docs Drop Claims
• Beasley Allen And J&J Tussle Over Atty Sanctions Bid
• Weil Litigation Leaders Jump To Paul Weiss In NY
• MVP: Williams & Connolly's David I. Berl
• Pfizer Unit Can't Get $75M Left In Insider Trading Deal Fund
• High Court Urged To Let Courts Scrutinize Agency Rulings
• DC Circ. Wonders Where To Land On Terrorism Liability Claims
• Blood Vessel Maker Faces Investor Suit Over FDA Findings
• Costco Shoppers Say Kirkland Fish Oil Pills Hide Heart Risks
• Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer
• 10th Circ. Iffy On Colo.'s Remedy To Generic EpiPen Takings
• Failed W.Va. Patent Challenge Reveals Secret Prior Art's Risks
• J&J Wants Beasley Allen Atty Sanctioned For Depo No-Show
• Navigating Decentralized Clinical Trials With FDA's Guidance
• McGuireWoods Lands Health Ace, Former GC From Akin In NY
• Akin Adds Another Healthcare Expert To DC Lobbying Team
• MVP: Covington's Catherine Dargan
• The Bar Needs More Clarity On The Discovery Objection Rule
• McDermott Adds IP Pro From Gibson Dunn In Los Angeles
• 'You Stepped Over The Line': Judge Rips Quinn Emanuel Atty
• J&J Posts $1.17B Bond For Del. Merger Milestone Appeal
• Melinta Obtains Ban On Generic Antibiotic Injections In IP Row
• Pa. Lab Seeks Ad Coverage For Libel Suit Over COVID Tests
• $100M Deal In Suit Over Walgreens Rx Prices Gets First OK
• Medical Group Wants Justices To Review IP Safe Harbor Fight
• Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting
• How Patent Landscape Analysis Drives Business Growth
• MVP: Ropes & Gray's Amanda Austin
• Supreme Court Turns Down 3 Patent Cases
• Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
• Natera Exec Calls Guardant's Cancer Test Claims 'Dangerous'
• SEC-Sanctioned Accounting Firm Sued Over Pre-IPO Work
• PBMs Denied Breakup Of Combined FTC Insulin Price Trial
• Despite Vaccine Spotlight, RFK Jr. A Health Policy 'Unknown'
• Ariz. Judge Will Decide Proper Venue For CVS Antitrust Suit
• DEA Judge Nixes Vet Group's Bid To Take Part In Pot Hearings
• In Terror Case, DC Circ. Must Weigh Justices' Twitter Ruling
• Marching In On Orange Book Drugs May Have Limited Effect
• Abbott Inks $8M Deal With Healthcare Fraudster In TM Suit
• Ayahuasca Church Urges Justices To Hear Discovery Case
• Teva Defends Mifepristone Antitrust Case Against Corcept
• Attys Get 'Final Warning' In Tepezza Hearing Loss MDL
• HOA's Insurer Says Pool Chemical Injury Suits Aren't Covered
• Being A Navy Reservist Makes Me A Better Lawyer
• Orrick Trial Partner Joins Morgan Lewis In Boston
• Pharma Biz To Pay $47M To Settle Feds' Kickback Claims
• Sterilization Co. Cosmed Hits Ch. 11 Amid Cancer Claims
• Trump's RFK Jr. Pick For HHS Draws Its Share Of Critics
• Senate Panel Delays Votes On Patent Eligibility And PTAB Bills
• Judge Finds Dexcom Infringed Abbott Patent That Hung Jury
• Takeda Rips Cert. Order's 'Whale Of Assumption' At 9th Circ.
• Incoming Admin May Shake Up Life Sciences Regulation
• Boehringer Says Inhaler Antitrust Suit 'Fails On Its Face'
• Next Steps In The $2.8B Blue Cross Payout To Providers
• Boeing Could Sell Navigation Unit For $6B, And More Rumors
• Trump Picks RFK Jr. To Lead Health & Human Services
• So You Want To Move Your Law Practice To Canada, Eh?
• Guardant Atty Accuses Natera CEO Of Dishonesty At Trial
• Damages Limited In AGs' Generic Drug Price-Fixing Case
• Honey Pot Greenwashes 'Plant-Derived' Products, Suit Says
• Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks
• Alnylam Says It's Not A 'Patent Troll' In Vax IP Row
• TikTok Asks To Keep NC AG's Addiction Complaint Redacted
• Baltimore Wins $266M In McKesson, Cencora Opioid Case
• Biotech Brass Misled Investors About Cancer Drugs, Suit Says
• What To Expect Next From Federal Health Tech Regulation
• Trump's Choice Of Matt Gaetz For AG Hints At Cannabis Policy
• Trump Rollback Of Biden Enviro Policies: What To Expect
• Trump Taps Elon Musk To Head New 'Gov't Efficiency' Dept.
• Masimo Can't Tie Alleged IP Theft To Apple Profits, Expert Says
• Guardant CEO Says Rival's False Ads Hurt 'Beautiful Baby'
• Justices Told Fed. Circ. Overstep Claims Are 'Simply Incorrect'
• HIV Drug Buyers Want Gilead Product Switch Claims Revived
• J&J Says HHS Is Thwarting Transparency Of Drug Discounts
• Elanco Pays $15M SEC Fine To Settle Sales Incentive Claims
• GOP Reps. Propose Another Bill On TRIPS Waivers
• Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
• Takeaways From State Votes On Abortion In The 2024 Election
• Key Territory-Split Licensing Lessons For Life Sciences Cos.
• Feds Can Hold Proceeds During Chinese Syringe Duties Fight
• DOJ Suing To Block UnitedHealth Unit's $3.3B Amedisys Deal
• Legislation Most Likely To Pass In Lame Duck Session
• NJ Ethics Board Escapes Contempt Bid In Retaliation Fight
• Apple Didn't Hire Cercacor CTO To Steal Watch IP, Ex-VP Says
• 5th Time Not The Charm For 'Stale' Dow Implant Check Fight
• J&J Talc Unit Must Revise Ch. 11 Plan, Insurers Say
• Fed. Circ. Unclear If Teva Inhaler IP Belongs In Orange Book
• Ill. Judge Sends Abbott Safety Gear OT Suit To Ohio
• Ex-Elanco IP Lawyer Lodges Gender Discrimination Suit
• Judge Lets Plaintiffs Drop Kroger Pain Patch Suit
• Justices Must Weigh Reach Of Civil RICO In Cannabis Case
• White & Case Adds Life Sciences IP Atty From A&O Shearman
• Litigation Strategies In View Of New Double Patenting Rulings
• Promoting Diversity In The Selection Of ADR Neutrals
• Wuhan Chemical Co. Charged In Latest China Fentanyl Bust
• Teva Fails To Convince Judge Inhaler Patents Require Drug
• Masimo Spinoff's Ex-CTO Denies Giving Apple Trade Secrets
• Ex-Natera VP Defends Ad Campaign Against Rival Guardant
• 3rd Circ. Says Tainted Bayer Antifungals Clearly 'Worth Less'
• FDA Wants Ineffective Decongestant Removed From Market
• Ill. Judge Anticipates 'Massive' Outcome Investor Restitution
• Researcher Sues DEA Over Pot Rescheduling Process
• Eye Drop Maker To Pay $3.6M To Settle Class Claims
• Teva Can't End Inhaler Antitrust Suit But Gets Claim Nixed
• Same PBM Conduct Means Same Insulin Price Trial, FTC Says
• Playing Ultimate Makes Us Better Lawyers
• LeBron Eyes Media Merger, AI Startup IPO, And More Rumors
• Masimo Expert Cites LED And Foam As Evidence Apple Stole IP
• Natera Declared 'War' On Guardant, Jury Told At Trial's Start
• Trump's Win Likely To Spur Deals For Capital Markets Attys
• After Electoral Defeats, Cannabis Advocates Eye Next Steps
• Sanctioned Supplier, Abbott Strike Deal Over TM Judgment
• Medtronic Says Axonics Misled Jury To Beat Patent Case
• Feds Fight Philly Injection Site Group's 3rd Circ. Appeal
• Insurers Urge Del. Justices To Reverse Drug Co. Policy Ruling
• Feds Look To Halt Vitamin Co. Payouts Amid $1.4M Tax Fight
• Business Groups Urge Calif. Justices To Nix HIV Drug Ruling
• What A Second Trump Term Could Mean For FDA And CPSC
• E-Discovery Quarterly: Recent Rulings On Metadata
• Tobacco Cos. Side With FDA In Menthol Cigarette Ban Fight
• How The Patent System May Look After Trump's Return
• Trump Has Official Immunity. What About His Aides?
• How Trump Can Quash His Criminal Cases
• An Early Look At Trump's Supreme Court Shortlist
• GOP's Senate Win Hands Future Of The Judiciary To Trump
• The Firms With An Inside Track To A New Trump Admin
• Cannabis And Psychedelic Reform Bids Fail In Multiple States
• Wash. AG With Antitrust Focus Wins Governor's Race
• Apple Stole Masimo Sensor IP, Calif. Judge Told At Trial's Start
• Eye-Rolling Must Stop, Judge Warns Before False Ad Trial
• Target Inks Individual Deals Over 'Non-Drowsy' Flu Medicine
• Thermo Fisher Antitrust Counsel Returns To Ropes & Gray
• Lab Owner's Atty DQ'd After Repping Doctor In Fraud Inquiry
• McDermott Lands Pharma IP Attorney From DLA Piper In SF
• On The Ground: How Attorneys Safeguarded The Election
• Abortion Ballot Tracker: 7 States Add Protections As Fla. Effort Fails
• Kroger, State AGs Finalize Sprawling $1.37B Opioid Deal
• Whistleblowers Win Cut Of Medical Kickback Settlement
• Sanctions Lessened Against Testing Co. That 'Duped' Judge
• Startup Beats $460M Cancer Trade Secrets Case In Delaware
• Del. Judge To Approve Avante Ch. 11 Financing
• Cigna Scores $7.3M Verdict Against Fla. Drug Testing Labs
• Late New Evidence Can't Revive Investor Suit, Judge Says
• Yale Gets 2nd Circ. Win In COVID Test Reimbursement Row
• Errors Lower Fee Award For Athira Pharma Investors' Counsel
• NJ Judge Blocks Sun Pharma From Launching Hair Loss Drug
• Sandoz Wins $70M In Antitrust Suit Over Hypertension Drug
• Federal Trade Commission Atty Returns To Katten In DC
• PREVAIL Bill Is Another Misguided Attempt To Restrict PTAB
• Striking A Balance Between AI Use And Attorney Well-Being
• US IPO Activity Hits Standstill As Election Takes Center Stage
• Medisca Inks $22M FCA Deal Over Ingredient Pricing Scheme
• UChicago Must Face Student's Disability Discrimination Claim
• Jury To Decide Timing Issue In Insulin Patch Trade Secret Row
• Taxation With Representation: Kirkland, Davis Polk, Wachtell
• UK Litigation Roundup: Here's What You Missed In London
• Empathy In Mediation Offers A Soft Landing For Disputes
• Up To $755M Added To AZ Scuttled-Drug Damage Claim In Del.
• Being An Artist Makes Me A Better Lawyer
• 4 States To Vote On Expanding Cannabis Or Psychedelics